ClinicalTrials.gg
CompletedNCT01968668Updated Jul 16, 2021

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

A Phase 2 interventional study of BAY94-8862 and BAY94-8862 in Diabetic Nephropathies, sponsored by Bayer. Completed at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Enrollment
6th of 10
96 · median 108
Started
2013
with 1 other
Phase 2
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
5 of 10
Bayer

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 6th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 2nd registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

This study will be conducted in Japanese subjects with type 2 diabetes mellitus and the clinical diagnosis of Diabetic Nephropathy( DN) using a multi-center, randomized, adaptive, double-blind, placebo-controlled, parallel-group design.

Primary objective of the study is investigate the change of Urinary Albumin to Creatine Ratio (UACR) after treatment with different oral doses of BAY94-8862 given once daily from baseline to Visit 8 (Day 90)

03

Conditions studied

  • Diabetic Nephropathies

Keywords

  • BAY94-8862
  • MR antagonist
  • Diabetic nephropathy
  • Japanese patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese subjects with type 2 diabetes mellitus and a clinical diagnosis of DN (Diabetic Nephropathy) treated with at least the minimal recommended dose of an Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blocker (ARB)
  • Subjects with a clinical diagnosis of Diabetic Nephropathy (DN) based on at least 1 of the following criteria:

    • Persistent very high albuminuria defined as Urinary Albumin to Creatine Ratio (UACR) of >/=300 mg/g (>/=34 mg/mmol) in 2 out of 3 first morning void samples and estimated (eGFR) >/=30 mL/min/1.73 m2 but \<90 mL/min/1.73 m2 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) or
    • Persistent high albuminuria defined as UACR of >/=30 mg/g but \<300 mg/g (>/=3.4 mg/mmol but \<34 mg/mmol) in 2 out of 3 first morning void samples and eGFR>/=30 mL/min/1.73 m2 but \<90 mL/min/1.73 m2 (CKD-EPI)
  • Serum potassium \</=4.8 mmol/L at both the run-in visit and the screening visit

Exclusion criteria

Exclusion Criteria:

  • Non-diabetic renal disease (confirmed by )
  • Known bilateral renal artery stenosis (>75%)
  • (HbA1c) >12% at the run-in visit or the screening visit
  • UACR >3000 mg/g (339 mg/mmol) in any of the urinary first morning void samples at the run-in visit or screening visit
  • Hypertension with mean sitting systolic blood pressure (SBP) >/=180 mmHg or mean sitting diastolic blood pressure (DBP) >/=110 mmHg at the run-in visit or mean sitting SBP >/=160 mmHg or mean sitting DBP >/=100 mmHg at the screening visit
  • Subjects with a clinical diagnosis of heart failure with reduced (HFrEF) and persistent symptoms ( class II-IV) at the run-in visit
  • Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    BAY94-8862 (1.25 mg)

    Drug: BAY94-8862

  • Experimental
    BAY94-8862 (2.5 mg)

    Drug: BAY94-8862

  • Experimental
    BAY94-8862 (5 mg )

    Drug: BAY94-8862

  • Experimental
    BAY94-8862 (7.5 mg)

    Drug: BAY94-8862

  • Experimental
    BAY94-8862 (10 mg)

    Drug: BAY94-8862

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    BAY 94-8862 (15 mg)

    Drug: BAY 94-8862

  • Experimental
    BAY 94-8862 (20 mg)

    Drug: BAY 94-8862

Interventions

  • 1.25 mg BAY94-8862 tablet once daily in the morning

  • 2.5 mg BAY94-8862 tablet once daily in the morning

  • 5 mg BAY94-8862 tablet once daily in the morning

  • 7.5 mg BAY94-8862 tablet once daily in the morning

  • 10 mg BAY94-8862 tablet once daily in the morning

  • DrugPlacebo

    Placebo tablet once daily in the morning

  • 15 mg BAY 94-8862 tablet once daily in the morning

  • 20 mg BAY 94-8862 tablet once daily in the morning

06

What researchers measure

Primary outcomes

  1. Change of urinary albumin-to creatinine ratio

    Time frame: Baseline and 90 days

Secondary outcomes

  1. Change in serum potassium concentration

    Time frame: Baseline and 90 days

07

Study locations

16 sites
  • Nagoya, Aichi 456-0058, Japan
  • Nagoya, Aichi 466-0815, Japan
  • Saijo, Ehime 793-0027, Japan
  • Kurume, Fukuoka 830-8522, Japan
  • Kurume, Fukuoka 830-8543, Japan
  • Obihiro, Hokkaido 080-0848, Japan
  • Amagasaki, Hyogo 660-8550, Japan
  • Koga, Ibaraki 306-0232, Japan
  • Tsuchiura, Ibaraki 300-0835, Japan
  • Tsukuba, Ibaraki 305-0812, Japan
  • Kahoku-gun, Ishikawa 920-0293, Japan
  • Sakaide, Kagawa 762-0007, Japan
  • Izumisano, Osaka 598-8577, Japan
  • Yao, Osaka 581-0011, Japan
  • Katsushika, Tokyo 125-0054, Japan
  • Osaka, 530-0001, Japan
08

References and documents

Publications

  • Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. PubMed 31583611 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Oct 2014, 11 months.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2013
First posted
Oct 24, 2013
StartActual
Oct 28, 2013
Primary completionActual
Oct 9, 2014
CompletionActual
Nov 7, 2014
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01968668
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 24, 2013
Start date
Oct 28, 2013
Primary completion
Oct 9, 2014
Completion
Nov 7, 2014
Last update
Jul 16, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion